RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+5.19%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.34B
AUM Growth
+$16.4M
Cap. Flow
-$1.65M
Cap. Flow %
-0.12%
Top 10 Hldgs %
51.3%
Holding
73
New
15
Increased
18
Reduced
22
Closed
16
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.7 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
0.5 years

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$54.1M
2
BSX icon
Boston Scientific
BSX
+$40.3M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$40.2M
4
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
+$34.8M
5
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$22.4M

Top Sells

Rank Stock Value
1
RAD
Rite Aid Corporation
RAD
+$49M
2
CMRX icon
Chimerix, Inc.
CMRX
+$40.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.8M
4
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$33.8M
5
INCY icon
Incyte
INCY
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 87.97%
2 Miscellaneous 9.9%
3 Communication Services 1.56%
4 Industrials 0.57%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NSTG
26
DELISTED
NanoString Technologies, Inc.
NSTG
$20M 1.49%
1,357,692
-27,949
-2% -$411K
2013 Q3
9 quarters
WVE icon
27
Wave Life Sciences
WVE
$615M
$18.3M 1.37%
+1,213,627
New +$19M
2015 Q4
0 quarters
CTMX icon
28
CytomX Therapeutics
CTMX
$486M
$14.4M 1.08%
+738,356
New +$11.7M
2015 Q4
0 quarters
HNT
29
DELISTED
HEALTH NET INC
HNT
$12.4M 0.93%
181,029
+1,800
+1% +$115K
2014 Q3
5 quarters
ELGX
30
DELISTED
Endologix Inc
ELGX
$9.97M 0.75%
+100,718
New +$10.8M
2015 Q4
0 quarters
OXFD
31
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$9.89M 0.74%
860,288
-167,844
-16% -$2.08M
2013 Q4
8 quarters
CRL icon
32
Charles River Laboratories
CRL
$14.4B
$9.84M 0.74%
+122,400
New +$8.83M
2015 Q4
0 quarters
TRIV
33
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$9.73M 0.73%
1,462,762
-1,221
-0.1% -$8.1K
2014 Q2
6 quarters
FATE icon
34
Fate Therapeutics
FATE
$228M
$7.99M 0.6%
2,371,001
+296,165
+14% +$1.24M
2015 Q2
2 quarters
PGND
35
DELISTED
PRESS GANEY HOLDINGS INC COM STK (DE)
PGND
$7.56M 0.57%
239,616
+154,650
+182% +$4.93M
2015 Q3
1 quarter
BPMC icon
36
DELISTED
Blueprint Medicines
BPMC
$7.29M 0.55%
276,687
-90,798
-25% -$2.04M
2015 Q2
2 quarters
GBT
37
DELISTED
Global Blood Therapeutics, Inc.
GBT
$7.07M 0.53%
218,718
-44,174
-17% -$1.91M
2015 Q3
1 quarter
DRRX icon
38
DELISTED
DURECT Corp
DRRX
$5.81M 0.43%
262,842
+1,510
+0.6% +$32.7K
2015 Q3
1 quarter
NVTA
39
DELISTED
Invitae Corporation
NVTA
$5.42M 0.41%
660,129
– –
2015 Q1
3 quarters
CASC
40
DELISTED
Cascadian Therapeutics, Inc.
CASC
$5.17M 0.39%
388,550
-213,948
-36% -$3.68M
2015 Q2
2 quarters
PRQR icon
41
ProQR Therapeutics
PRQR
$207M
$4.84M 0.36%
557,193
-103,623
-16% -$1.19M
2014 Q3
5 quarters
PFE icon
42
Pfizer
PFE
$167B
$4M 0.3%
+130,485
New +$4.1M
2015 Q4
0 quarters
CARM icon
43
DELISTED
Carisma Therapeutics
CARM
$2.64M 0.2%
43,793
+1,375
+3% +$78.1K
2014 Q4
4 quarters
CFMS
44
DELISTED
Conformis, Inc. Common Stock
CFMS
$2.17M 0.16%
5,028
-22,526
-82% -$11.3M
2015 Q3
1 quarter
CELG
45
DELISTED
Celgene Corp
CELG
$1.2M 0.09%
+10,055
New +$1.16M
2015 Q4
0 quarters
IHF icon
46
iShares US Healthcare Providers ETF
IHF
$1.41B
$562K 0.04%
+22,600
New +$561K
2015 Q4
0 quarters
CCXI icon
47
DELISTED
ChemoCentryx, Inc.
CCXI
$512K 0.04%
63,189
-437,426
-87% -$3.1M
2015 Q1
3 quarters
SRRA
48
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$373K 0.03%
620
+160
+35% +$108K
2015 Q3
1 quarter
LAB icon
49
Standard BioTools
LAB
$255M
$352K 0.03%
32,561
+7,978
+32% +$78.3K
2014 Q2
6 quarters
XBI icon
50
State Street SPDR S&P Biotech ETF
XBI
$9.7B
$317K 0.02%
4,530
-4,720
-51% -$322K
2015 Q3
1 quarter
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2015 Portfolio in Review

As of Q4 2015, Redmile Group held 73 positions worth $1.34B, up 1.2% from $1.32B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Redmile Group's Q4 2015 filing shows 15 new, 18 increased, 22 reduced and 16 closed positions. Its largest new stake was Boston Scientific: 2,251,020 shares worth $41.5M. The largest sale was Rite Aid Corporation, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Communication Services.

  • Redmile Group's largest Q4 2015 buy was Boston Scientific: 2,251,020 shares worth $41.5M.
  • Redmile Group added most to Clovis Oncology, Inc. in Q4 2015, an estimated $54.1M increase.
  • Redmile Group's biggest Q4 2015 reduction was Incyte, cutting an estimated $28.5M.
  • Redmile Group fully exited Rite Aid Corporation in Q4 2015, selling an estimated $49M.
  • Redmile Group's ten largest holdings make up 51% of its $1.34B portfolio in Q4 2015.
  • Redmile Group opened 15 new positions and closed 16 in Q4 2015.
  • Redmile Group's portfolio value rose 1.2% quarter-over-quarter to $1.34B.

Based on Redmile Group's 13F filing for Q4 2015, filed 16 Feb 2016.